SynthesisCancer research and treatment2026
Effectiveness of Radiotherapy for Hepatocellular Carcinoma with Lymph Node Metastasis: A Meta-Analysis.
Synthesis in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeLymph node metastasis (LNM) of hepatocellular carcinoma (HCC) carries a poor prognosis; however, no standard treatment has been established. Radiotherapy (RT) has demonstrated favorable tumor response, with the advantage of being less affected by anatomical hindrances. MATERIALS AND
methodsDatabases were searched up to April 2024. The inclusion criteria were ≥ 5 patients with HCC LNM, studies that performed external RT, and reporting survival or response rate (RR). The main effect measures are pooled 1- and 2-year overall survival (OS) rates, RR, and grade ≥ 3 complications.
resultsTwelve studies involving 825 patients were included. The pooled 1-year OS rate and 2-year OS rate were 49.3% (95% confidence interval [CI], 39.2 to 59.4) and 24.5% (95% CI, 17.0 to 34.0), respectively. The median OS ranged from 5.8 to 29.7 months, with a median value of 9.7 months. In one study, 14.7% of patients were prescribed an immunoagent. In other studies, some patients received sorafenib, but no specific systemic therapy was performed for the majority. The pooled RR was 75.1% (95% CI, 66.9 to 81.8). The pooled RR of high dose and low dose groups was 83.8% (95% CI, 76.3 to 89.3) vs. 55.6% (95% CI, 44.4 to 66.3), respectively (p < 0.001). The pooled rate of grade ≥ 3 gastrointestinal toxicity was 3.7% (95% CI, 2.1 to 6.6).
conclusionRT is an effective and feasible palliative option for HCC LNM. Further research of combined treatment with novel systemic agents are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.